The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma

BACKGROUND: Sorafenib is the drug of choice in the treatment of advanced hepatocellular carcinoma (HCC). Beneficial effects are limited by mechanisms of chemoresistance, which include downregulation and/or impaired function of plasma membrane transporters accounting for drug uptake. The organic cati...

Descripción completa

Detalles Bibliográficos
Autores principales: Geier, Andreas, Macias, Rocio I.R., Bettinger, Dominik, Weiss, Johannes, Bantel, Heike, Jahn, Daniel, Al-Abdulla, Ruba, Marin, Jose J.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362528/
https://www.ncbi.nlm.nih.gov/pubmed/28178663
http://dx.doi.org/10.18632/oncotarget.15029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362528/
https://www.ncbi.nlm.nih.gov/pubmed/28178663
http://dx.doi.org/10.18632/oncotarget.15029

Ejemplares similares